chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Dose was given from a open vial 9 day out; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose was given from a open vial 9 day out) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    In 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose was given from a open vial 9 day out). In 2021, EXPIRED PRODUCT ADMINISTERED (Dose was given from a open vial 9 day out) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were mentioned. No treatment details were reported.
Sex: F
Vaccine: COVID19
Symptoms: Injection site warmth, Vaccination site erythema, Vaccination site induration, Vaccination site pruritus
Clinical narrative: had the same thing( arm was red, hot, hard and itchy at injection site); had the same thing( arm was red, hot, hard and itchy at injection site); had the same thing( arm was red, hot, hard and itchy at injection site); had the same thing( arm was red, hot, hard and itchy at injection site); This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE WARMTH (had the same thing( arm was red, hot, hard and itchy at injection site)), VACCINATION SITE INDURATION (had the same thing( arm was red, hot, hard and itchy at injection site)), VACCINATION SITE PRURITUS (had the same thing( arm was red, hot, hard and itchy at injection site)) and VACCINATION SITE ERYTHEMA (had the same thing( arm was red, hot, hard and itchy at injection site)) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Jul-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Aug-2021, the patient experienced INJECTION SITE WARMTH (had the same thing( arm was red, hot, hard and itchy at injection site)), VACCINATION SITE INDURATION (had the same thing( arm was red, hot, hard and itchy at injection site)), VACCINATION SITE PRURITUS (had the same thing( arm was red, hot, hard and itchy at injection site)) and VACCINATION SITE ERYTHEMA (had the same thing( arm was red, hot, hard and itchy at injection site)). At the time of the report, INJECTION SITE WARMTH (had the same thing( arm was red, hot, hard and itchy at injection site)), VACCINATION SITE INDURATION (had the same thing( arm was red, hot, hard and itchy at injection site)), VACCINATION SITE PRURITUS (had the same thing( arm was red, hot, hard and itchy at injection site)) and VACCINATION SITE ERYTHEMA (had the same thing( arm was red, hot, hard and itchy at injection site)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment history was reported.  No concomitant medications were reported
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue, Vaccination site anaesthesia
Clinical narrative: not able to get the second dose; left arm felt numb; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ANAESTHESIA (left arm felt numb) and PRODUCT DOSE OMISSION ISSUE (not able to get the second dose) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A21B) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Apr-2021, the patient experienced VACCINATION SITE ANAESTHESIA (left arm felt numb). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (not able to get the second dose). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Numbness, at a dose of UNK dosage form. At the time of the report, VACCINATION SITE ANAESTHESIA (left arm felt numb) and PRODUCT DOSE OMISSION ISSUE (not able to get the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Illness, Product dose omission issue, Pyrexia
Clinical narrative: fever; sick; did not get the second dose; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever), ILLNESS (sick) and PRODUCT DOSE OMISSION ISSUE (did not get the second dose) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever), ILLNESS (sick) and PRODUCT DOSE OMISSION ISSUE (did not get the second dose). At the time of the report, PYREXIA (fever), ILLNESS (sick) and PRODUCT DOSE OMISSION ISSUE (did not get the second dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported. No treatment medication was reported.
Sex: U
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Have had a pretty nasty headache since that just won't go away; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Have had a pretty nasty headache since that just won't go away) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    In August 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (Have had a pretty nasty headache since that just won't go away). At the time of the report, HEADACHE (Have had a pretty nasty headache since that just won't go away) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. No treatment medications were provided.   Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: Blood pressure measurement, Palpitations
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Heart palpatations) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported.In January 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In January 2021, the patient experienced PALPITATIONS (Heart palpatations). At the time of the report, PALPITATIONS (Heart palpatations) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2021, Blood pressure measurement: high (High) Elevated BP.The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.No concomitant medications were provided by reporter. No treatment medications were provided by reporter. Additional information reported include that the patient was asking whether be vaccinated further and to mention the vaccine name as well.
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Didn't get the 2nd dose yet/more than 36 days from 1st vaccination; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Didn't get the 2nd dose yet/more than 36 days from 1st vaccination) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Didn't get the 2nd dose yet/more than 36 days from 1st vaccination). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Didn't get the 2nd dose yet/more than 36 days from 1st vaccination) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported. No treatment medication were reported.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: After receiving 1st dose, he had little soreness, pain in right arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (After receiving 1st dose, he had little soreness, pain in right arm) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (After receiving 1st dose, he had little soreness, pain in right arm). At the time of the report, PAIN IN EXTREMITY (After receiving 1st dose, he had little soreness, pain in right arm) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       No concomitant medications were reported. No treatment details were reported.   This case was linked to MOD-2021-296101 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: Vaccime side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Vaccime side effects) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Vaccime side effects). At the time of the report, VACCINATION COMPLICATION (Vaccime side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Body temperature, Dizziness, Extra dose administered, Fatigue
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (Weakness), DIZZINESS (Dizzy/ dizziness), FATIGUE (feeling tired/ exhausted), PYREXIA (He had fever of 100 degrees/ experienced temperature) and EXTRA DOSE ADMINISTERED (he received the third dose) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The patient's past medical history included Heart attack, Enlarged prostate and Non-Hodgkin's lymphoma (He had cancer 20 years ago). Concurrent medical conditions included Depression and Blood pressure abnormal (Blood pressure).On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2021, the patient experienced ASTHENIA (Weakness), DIZZINESS (Dizzy/ dizziness), FATIGUE (feeling tired/ exhausted) and PYREXIA (He had fever of 100 degrees/ experienced temperature). On 23-Aug-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXTRA DOSE ADMINISTERED (he received the third dose). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. On 23-Aug-2021, EXTRA DOSE ADMINISTERED (he received the third dose) had resolved. At the time of the report, ASTHENIA (Weakness), DIZZINESS (Dizzy/ dizziness), FATIGUE (feeling tired/ exhausted) and PYREXIA (He had fever of 100 degrees/ experienced temperature) outcome was unknown.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Body temperature: 100 (High) 100 degrees. No concomitant medications were reported. Patient reported that he did not experience any adverse events with the first two doses.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (Weakness), DIZZINESS (Dizzy/ dizziness), FATIGUE (feeling tired/ exhausted), PYREXIA (He had fever of 100 degrees/ experienced temperature) and EXTRA DOSE ADMINISTERED (he received the third dose) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The patient's past medical history included Heart attack, Enlarged prostate and Non-Hodgkin's lymphoma (He had cancer 20 years ago). Concurrent medical conditions included Depression and Blood pressure abnormal (Blood pressure).On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2021, the patient experienced ASTHENIA (Weakness), DIZZINESS (Dizzy/ dizziness), FATIGUE (feeling tired/ exhausted) and PYREXIA (He had fever of 100 degrees/ experienced temperature). On 23-Aug-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXTRA DOSE ADMINISTERED (he received the third dose). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. On 23-Aug-2021, EXTRA DOSE ADMINISTERED (he received the third dose) had resolved. At the time of the report, ASTHENIA (Weakness), DIZZINESS (Dizzy/ dizziness), FATIGUE (feeling tired/ exhausted) and PYREXIA (He had fever of 100 degrees/ experienced temperature) outcome was unknown.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Body temperature: 100 (High) 100 degrees. No concomitant medications were reported. Patient reported that he did not experience any adverse events with the first two doses.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Vaccine administered from a vial that has possibly been punctured for 48 hours.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine administered from a vial that has possibly been punctured for 48 hours.) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Aug-2021 at 9:40 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine administered from a vial that has possibly been punctured for 48 hours.). On 25-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine administered from a vial that has possibly been punctured for 48 hours.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medication information was reported. No treatment medications were reported.  The patient given dose was punctured before 96 hours of administration.   Most recent FOLLOW-UP information incorporated above includes: On 29-Aug-2021: Follow-up received added Patient demographics, updated event outcome.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Received the first dose of the Moderna COVID19 vaccine being 16,5 years old on march; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received the first dose of the Moderna COVID19 vaccine being 16,5 years old on march) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     No Medical History information was reported.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received the first dose of the Moderna COVID19 vaccine being 16,5 years old on march). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received the first dose of the Moderna COVID19 vaccine being 16,5 years old on march) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.    Concomitant medication was not reported. Treatment information not reported.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus, Vaccination site rash, Vaccination site reaction, Vaccination site warmth
Clinical narrative: COVID arm; Arm of injection is warm to touch; A rash appeared at the site of injection. The rash is red and a little itchy.; A rash appeared at the site of injection. The rash is red and a little itchy.; A rash appeared at the site of injection. The rash is red and a little itchy.; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (COVID arm), VACCINATION SITE WARMTH (Arm of injection is warm to touch), VACCINATION SITE PRURITUS (A rash appeared at the site of injection. The rash is red and a little itchy.), VACCINATION SITE RASH (A rash appeared at the site of injection. The rash is red and a little itchy.) and VACCINATION SITE ERYTHEMA (A rash appeared at the site of injection. The rash is red and a little itchy.) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003F21A) for COVID-19 vaccination.     No medical history was reported.     On 13-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Aug-2021, the patient experienced VACCINATION SITE REACTION (COVID arm), VACCINATION SITE WARMTH (Arm of injection is warm to touch), VACCINATION SITE PRURITUS (A rash appeared at the site of injection. The rash is red and a little itchy.), VACCINATION SITE RASH (A rash appeared at the site of injection. The rash is red and a little itchy.) and VACCINATION SITE ERYTHEMA (A rash appeared at the site of injection. The rash is red and a little itchy.). The patient was treated with LORATADINE (CLARITIN [LORATADINE]) on 24-Aug-2021 for Adverse event, at a dose of 1 dosage form. At the time of the report, VACCINATION SITE REACTION (COVID arm), VACCINATION SITE WARMTH (Arm of injection is warm to touch) and VACCINATION SITE RASH (A rash appeared at the site of injection. The rash is red and a little itchy.) outcome was unknown and VACCINATION SITE PRURITUS (A rash appeared at the site of injection. The rash is red and a little itchy.) and VACCINATION SITE ERYTHEMA (A rash appeared at the site of injection. The rash is red and a little itchy.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant product use was provided by the reporter.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Expired product administered, Influenza like illness, Myalgia
Clinical narrative: Severe pain in her joint (mainly wrists, elbows and knees); Patient was very achy for about 2 and a half days; No energy; Almost like she had the flu; Received a probably expired vaccine; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (No energy), INFLUENZA LIKE ILLNESS (Almost like she had the flu), EXPIRED PRODUCT ADMINISTERED (Received a probably expired vaccine), ARTHRALGIA (Severe pain in her joint (mainly wrists, elbows and knees)) and MYALGIA (Patient was very achy for about 2 and a half days) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031B21A and 003A21A) for COVID-19 vaccination.     Medical history was not provided by reporter.  Concomitant products included FLUOXETINE HYDROCHLORIDE (PROZAC), ACETYLSALICYLIC ACID (ASPIRIN 81), ROSUVASTATIN CALCIUM (CRESTOR) and OMEPRAZOLE (PROTONIX [OMEPRAZOLE]) for an unknown indication.   On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Apr-2021, the patient experienced ASTHENIA (No energy), INFLUENZA LIKE ILLNESS (Almost like she had the flu), EXPIRED PRODUCT ADMINISTERED (Received a probably expired vaccine) and MYALGIA (Patient was very achy for about 2 and a half days). On 12-Apr-2021, the patient experienced ARTHRALGIA (Severe pain in her joint (mainly wrists, elbows and knees)). The patient was treated with IBUPROFEN for Pain, at a dose of 800 mg. On 08-Apr-2021, EXPIRED PRODUCT ADMINISTERED (Received a probably expired vaccine) had resolved. On 11-Apr-2021, ASTHENIA (No energy), INFLUENZA LIKE ILLNESS (Almost like she had the flu) and MYALGIA (Patient was very achy for about 2 and a half days) had resolved. At the time of the report, ARTHRALGIA (Severe pain in her joint (mainly wrists, elbows and knees)) outcome was unknown.            Treatment also included an additional medication for pain.  Labs and diagnostic testing included unspecified blood tests with unremarkable results and an assessment by a Rheumatologist, with unremarkable results.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Dry mouth
Clinical narrative: Sudden Dry mouth; This spontaneous case was reported by a nurse and describes the occurrence of DRY MOUTH (Sudden Dry mouth) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Aug-2021, the patient experienced DRY MOUTH (Sudden Dry mouth). At the time of the report, DRY MOUTH (Sudden Dry mouth) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered DRY MOUTH (Sudden Dry mouth) to be possibly related.    The concomitant history was not reported. The treatment history was not provided. Patient  Patient experienced sudden dry mouth after first dose, another patient also experienced the same with same vial. No incidents found of improper storage refrigeration r freezing. Two remaining vials of same lot number are set aside. Clinic utilized a different lot number 047B21A no reported symptoms of dry mouth since implementation.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue, Viral load
Clinical narrative: Missed second shot more than 42 days after first shot; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed second shot more than 42 days after first shot) in a 5-week-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Diabetic and Hepatitis B.    On 15-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Aug-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed second shot more than 42 days after first shot). On 25-Aug-2021, PRODUCT DOSE OMISSION ISSUE (Missed second shot more than 42 days after first shot) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Viral load: high (High) High Viral load Hep B.         Concomitant drug was not reported.  Patient  had no side effects. She did not have a ride and she missed the second dose appointment. She was thinking about getting the second shot now.  Treatment medication was not reported.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Rash erythematous, Rash macular
Clinical narrative: red rash going into his armpit; red patch; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (red rash going into his armpit) and RASH MACULAR (red patch) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Aug-2021, the patient experienced RASH ERYTHEMATOUS (red rash going into his armpit) and RASH MACULAR (red patch). At the time of the report, RASH ERYTHEMATOUS (red rash going into his armpit) and RASH MACULAR (red patch) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported No treatment medications were reported.  Symptoms: It was reported that the patient had experienced a red line which was going into his armpit.
Age: 44.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: 2nd she got fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (2nd she got fever) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001A21A and 201B21A) for COVID-19 vaccination.     No medical history was reported.  Concomitant products included LAMOTRIGINE (LAMICTAL), OXCARBAZEPINE, GABAPENTIN, QUETIAPINE, HYDROCHLOROTHIAZIDE, OMEPRAZOLE, NALTREXONE, PROBIOTICS NOS, LYSINE, VITAMIN D3, MELATONIN, NATTOKINASE, RESVERATROL, MONOLAURIN [GLYCERINE MONOLAURATE], FISH OIL, VITAMIN C [ASCORBIC ACID] and LEVETIRACETAM (LEVRA) for an unknown indication.   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (2nd she got fever). At the time of the report, PYREXIA (2nd she got fever) outcome was unknown.            Concomitant medications also include sertiamen and IGG infusions weekly.  No treatment medication were reported.   This case was linked to MOD-2021-296523, MOD-2021-296516 (Patient Link).
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Too late to get the second dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Too late to get the second dose) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Too late to get the second dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Too late to get the second dose) had resolved.            Patient has not experienced any symptoms after the first dose. Concomitant medications include medications for type-2 diabetes mellitus and high blood pressure. Treatment information was not provided.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea
Clinical narrative: feels nauseous; has a headache; is fatigued; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (feels nauseous), HEADACHE (has a headache) and FATIGUE (is fatigued) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Seizures.    On 23-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Aug-2021, the patient experienced NAUSEA (feels nauseous), HEADACHE (has a headache) and FATIGUE (is fatigued). At the time of the report, NAUSEA (feels nauseous), HEADACHE (has a headache) and FATIGUE (is fatigued) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported by the reporter. No treatment was reported by the reporter.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blister, Erythema, Pruritus, Rash, Rash erythematous
Clinical narrative: Scabs on some lesions on the legs after 3rd shot; Red blisters get bigger after 3rd shot; Existing rash got worst after 3rd shot  and spread to both arms; Red rash on Legs, Thighs, and both arms after 3rd shot; Red blisters after 3rd shot; Some lesions itch intensely sometimes after 3rd shot; Some lesions itch intensely sometimes after 3rd shot; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (Red rash on Legs, Thighs, and both arms after 3rd shot), BLISTER (Red blisters after 3rd shot), SKIN LESION (Some lesions itch intensely sometimes after 3rd shot), PRURITUS (Some lesions itch intensely sometimes after 3rd shot) and SCAB (Scabs on some lesions on the legs after 3rd shot) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included CELECOXIB (CELEBREX) for Rash.    On 18-Aug-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Aug-2021, the patient experienced RASH ERYTHEMATOUS (Red rash on Legs, Thighs, and both arms after 3rd shot), BLISTER (Red blisters after 3rd shot), SKIN LESION (Some lesions itch intensely sometimes after 3rd shot), PRURITUS (Some lesions itch intensely sometimes after 3rd shot), ERYTHEMA (Red blisters get bigger after 3rd shot) and RASH (Existing rash got worst after 3rd shot  and spread to both arms). On 25-Aug-2021, the patient experienced SCAB (Scabs on some lesions on the legs after 3rd shot). The patient was treated with BETAMETHASONE at a dose of 0.05 % and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, RASH ERYTHEMATOUS (Red rash on Legs, Thighs, and both arms after 3rd shot), BLISTER (Red blisters after 3rd shot), SKIN LESION (Some lesions itch intensely sometimes after 3rd shot), PRURITUS (Some lesions itch intensely sometimes after 3rd shot), SCAB (Scabs on some lesions on the legs after 3rd shot) and ERYTHEMA (Red blisters get bigger after 3rd shot) outcome was unknown and RASH (Existing rash got worst after 3rd shot  and spread to both arms) had not resolved.        The  patient also states that she is also using Sarna lotion for itching.   This case was linked to MOD-2021-296629 (Patient Link).
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Scab, Skin lesion
Clinical narrative: Scabs on some lesions on the legs after 3rd shot; Red blisters get bigger after 3rd shot; Existing rash got worst after 3rd shot  and spread to both arms; Red rash on Legs, Thighs, and both arms after 3rd shot; Red blisters after 3rd shot; Some lesions itch intensely sometimes after 3rd shot; Some lesions itch intensely sometimes after 3rd shot; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (Red rash on Legs, Thighs, and both arms after 3rd shot), BLISTER (Red blisters after 3rd shot), SKIN LESION (Some lesions itch intensely sometimes after 3rd shot), PRURITUS (Some lesions itch intensely sometimes after 3rd shot) and SCAB (Scabs on some lesions on the legs after 3rd shot) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included CELECOXIB (CELEBREX) for Rash.    On 18-Aug-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Aug-2021, the patient experienced RASH ERYTHEMATOUS (Red rash on Legs, Thighs, and both arms after 3rd shot), BLISTER (Red blisters after 3rd shot), SKIN LESION (Some lesions itch intensely sometimes after 3rd shot), PRURITUS (Some lesions itch intensely sometimes after 3rd shot), ERYTHEMA (Red blisters get bigger after 3rd shot) and RASH (Existing rash got worst after 3rd shot  and spread to both arms). On 25-Aug-2021, the patient experienced SCAB (Scabs on some lesions on the legs after 3rd shot). The patient was treated with BETAMETHASONE at a dose of 0.05 % and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, RASH ERYTHEMATOUS (Red rash on Legs, Thighs, and both arms after 3rd shot), BLISTER (Red blisters after 3rd shot), SKIN LESION (Some lesions itch intensely sometimes after 3rd shot), PRURITUS (Some lesions itch intensely sometimes after 3rd shot), SCAB (Scabs on some lesions on the legs after 3rd shot) and ERYTHEMA (Red blisters get bigger after 3rd shot) outcome was unknown and RASH (Existing rash got worst after 3rd shot  and spread to both arms) had not resolved.        The  patient also states that she is also using Sarna lotion for itching.   This case was linked to MOD-2021-296629 (Patient Link).
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Depression, Disturbance in attention, Fatigue, Feeling abnormal, Herpes zoster
Clinical narrative: broke out in shingles; very debilitating nerve pain; eye sight is not good.; pain/depressed of being in chronic pain; small patch in the back; extreme fatigue; brain fog; hard time concentrating on things; depressed of being in chronic pain; got very very ill; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (got very very ill), HERPES ZOSTER (broke out in shingles), FEELING ABNORMAL (brain fog), DISTURBANCE IN ATTENTION (hard time concentrating on things) and DEPRESSION (depressed of being in chronic pain) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032M20A and 031M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sulfonamide allergy (Hives reaction), Penicillin allergy (Hives reaction), GERD since 2008 and Blood pressure high since 2015. Concomitant products included LISINOPRIL from 2015 to an unknown date, DEXLANSOPRAZOLE (DEXILANT) from 06-Jan-2008 to an unknown date, LEVOTHYROXINE SODIUM (SYNTHROID) from 2010 to an unknown date and HYDROCHLOORTHIAZIDE for an unknown indication.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In April 2021, the patient experienced FEELING ABNORMAL (brain fog), DISTURBANCE IN ATTENTION (hard time concentrating on things), DEPRESSION (depressed of being in chronic pain) and FATIGUE (extreme fatigue). On an unknown date, the patient experienced ILLNESS (got very very ill), HERPES ZOSTER (broke out in shingles), NEURALGIA (very debilitating nerve pain), VISION BLURRED (eye sight is not good.), PAIN (pain/depressed of being in chronic pain) and RASH (small patch in the back). The patient was treated with GABAPENTIN for Shingles, at a dose of 1 dosage form. At the time of the report, ILLNESS (got very very ill) had resolved, HERPES ZOSTER (broke out in shingles), PAIN (pain/depressed of being in chronic pain) and FATIGUE (extreme fatigue) had not resolved and FEELING ABNORMAL (brain fog), DISTURBANCE IN ATTENTION (hard time concentrating on things), DEPRESSION (depressed of being in chronic pain), NEURALGIA (very debilitating nerve pain), VISION BLURRED (eye sight is not good.) and RASH (small patch in the back) outcome was unknown.            Patient says she did dozens of medical tests to determine cause of nerve pain, but no reports provided.  She also took antivirals (18 days after starting shingles symptoms) to treat the symptoms.   This case was linked to MOD-2021-296653, MOD-2021-296286 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 31-Aug-2021: Follow-up received which includes patient height, weight, medical history and concomitant medications.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Illness, Neuralgia, Pain, Rash, Vision blurred
Clinical narrative: broke out in shingles; very debilitating nerve pain; eye sight is not good.; pain/depressed of being in chronic pain; small patch in the back; extreme fatigue; brain fog; hard time concentrating on things; depressed of being in chronic pain; got very very ill; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (got very very ill), HERPES ZOSTER (broke out in shingles), FEELING ABNORMAL (brain fog), DISTURBANCE IN ATTENTION (hard time concentrating on things) and DEPRESSION (depressed of being in chronic pain) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032M20A and 031M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sulfonamide allergy (Hives reaction), Penicillin allergy (Hives reaction), GERD since 2008 and Blood pressure high since 2015. Concomitant products included LISINOPRIL from 2015 to an unknown date, DEXLANSOPRAZOLE (DEXILANT) from 06-Jan-2008 to an unknown date, LEVOTHYROXINE SODIUM (SYNTHROID) from 2010 to an unknown date and HYDROCHLOORTHIAZIDE for an unknown indication.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In April 2021, the patient experienced FEELING ABNORMAL (brain fog), DISTURBANCE IN ATTENTION (hard time concentrating on things), DEPRESSION (depressed of being in chronic pain) and FATIGUE (extreme fatigue). On an unknown date, the patient experienced ILLNESS (got very very ill), HERPES ZOSTER (broke out in shingles), NEURALGIA (very debilitating nerve pain), VISION BLURRED (eye sight is not good.), PAIN (pain/depressed of being in chronic pain) and RASH (small patch in the back). The patient was treated with GABAPENTIN for Shingles, at a dose of 1 dosage form. At the time of the report, ILLNESS (got very very ill) had resolved, HERPES ZOSTER (broke out in shingles), PAIN (pain/depressed of being in chronic pain) and FATIGUE (extreme fatigue) had not resolved and FEELING ABNORMAL (brain fog), DISTURBANCE IN ATTENTION (hard time concentrating on things), DEPRESSION (depressed of being in chronic pain), NEURALGIA (very debilitating nerve pain), VISION BLURRED (eye sight is not good.) and RASH (small patch in the back) outcome was unknown.            Patient says she did dozens of medical tests to determine cause of nerve pain, but no reports provided.  She also took antivirals (18 days after starting shingles symptoms) to treat the symptoms.   This case was linked to MOD-2021-296653, MOD-2021-296286 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 31-Aug-2021: Follow-up received which includes patient height, weight, medical history and concomitant medications.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: Consumer answered yes when asked if they experienced any side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Consumer answered yes when asked if they experienced any side effects) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Consumer answered yes when asked if they experienced any side effects). At the time of the report, VACCINATION COMPLICATION (Consumer answered yes when asked if they experienced any side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Treatment information was reported. No Concomitant medications were reported.   This case was linked to MOD21-135558 (Patient Link).   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Cyst, Pain
Clinical narrative: painful cyst filled with fluid under armpit; painful cyst filled with fluid under armpit; This spontaneous case was reported by a consumer and describes the occurrence of CYST (painful cyst filled with fluid under armpit) and PAIN (painful cyst filled with fluid under armpit) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced CYST (painful cyst filled with fluid under armpit) and PAIN (painful cyst filled with fluid under armpit). At the time of the report, CYST (painful cyst filled with fluid under armpit) and PAIN (painful cyst filled with fluid under armpit) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication was not reported.  Relevant concomitant medications were not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 26-Aug-2021: Non-Significant Follow Up Appended- Ae contact info updated
Sex: U
Vaccine: COVID19
Symptoms: Abdominal pain upper
Clinical narrative: stomach cramps; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN UPPER (stomach cramps) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ABDOMINAL PAIN UPPER (stomach cramps). At the time of the report, ABDOMINAL PAIN UPPER (stomach cramps) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medication was mentioned. No Treatment medication was mentioned.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Myalgia, Vaccination site erythema, Vaccination site reaction
Clinical narrative: COVID arm; Arm only slightly sore; Red spot at injection site/Spots going half way down to elbow; Inappropriate schedule of vaccine administered; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (COVID arm), MYALGIA (Arm only slightly sore), VACCINATION SITE ERYTHEMA (Red spot at injection site/Spots going half way down to elbow) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Breast cancer (Patient had infiltrating lobular breast cancer in one breast and ductal cancer in the other.) and Vasculitis (Patient had vasculitis secondary to an allergic reaction 5-6 years ago to Reclast which patient was taking for osteoporosis.). Previously administered products included for an unreported indication: METHOTREXATE (Patient has been off the methotrexate for 2-3 weeks now.). Concurrent medical conditions included Drug allergy (Allergy to reclast.) and Immunocompromised.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Aug-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). On 25-Aug-2021, the patient experienced VACCINATION SITE REACTION (COVID arm), MYALGIA (Arm only slightly sore) and VACCINATION SITE ERYTHEMA (Red spot at injection site/Spots going half way down to elbow). On 23-Aug-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved. At the time of the report, VACCINATION SITE REACTION (COVID arm), MYALGIA (Arm only slightly sore) and VACCINATION SITE ERYTHEMA (Red spot at injection site/Spots going half way down to elbow) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment medications were provided.  Patient states that she is feeling fine. Patient also states that with the first two shots she couldn't tell anything and relates the symptoms having now to body producing antibodies.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Heavy menstrual bleeding, Myalgia, Vaccination site pain
Clinical narrative: loosing too much blood,spotting; just beeing so tired,is just tired; pain in her heel fasciitis with the heel spur; muscle pain in general; pain in her arm; This spontaneous case was reported by a consumer and describes the occurrence of HEAVY MENSTRUAL BLEEDING (loosing too much blood,spotting), FATIGUE (just beeing so tired,is just tired), ARTHRALGIA (pain in her heel fasciitis with the heel spur), MYALGIA (muscle pain in general) and VACCINATION SITE PAIN (pain in her arm) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     no medical history was reported.  Concomitant products included LOSARTAN and HYDROCHLOROTHIAZIDE (HCTZ) for an unknown indication.    On 25-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEAVY MENSTRUAL BLEEDING (loosing too much blood,spotting), FATIGUE (just beeing so tired,is just tired), ARTHRALGIA (pain in her heel fasciitis with the heel spur), MYALGIA (muscle pain in general) and VACCINATION SITE PAIN (pain in her arm). At the time of the report, HEAVY MENSTRUAL BLEEDING (loosing too much blood,spotting), FATIGUE (just beeing so tired,is just tired), ARTHRALGIA (pain in her heel fasciitis with the heel spur), MYALGIA (muscle pain in general) and VACCINATION SITE PAIN (pain in her arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medications were not reported.